ACG 2022 GERD guideline: key recommendations

Who it applies to

Adults with symptoms suggestive of GERD, including those with typical heartburn/regurgitation, extraesophageal symptoms, and PPI non-responders.

Key recommendations

• Patients with typical GERD symptoms without alarm features can be treated empirically with a trial of PPI therapy without initial endoscopy.
• Upper endoscopy is not required for diagnosis in most patients with uncomplicated heartburn but should be performed if alarm symptoms are present or risk factors for Barrett's esophagus exist.
• Ambulatory reflux monitoring (pH or pH-impedance) is recommended when the diagnosis is uncertain, particularly in PPI non-responders or before invasive anti-reflux procedures.
• In PPI non-responders with a prior objective diagnosis of GERD, further workup should focus on identifying causes such as inadequate adherence, functional esophageal disorders, or other esophageal conditions rather than simply escalating acid suppression.
• Routine testing for Helicobacter pylori is not recommended solely for the management of GERD.
• PPIs should be used at the lowest effective dose for symptom control, and long-term use should be periodically reassessed for continued need.
• Surgical or endoscopic anti-reflux therapy may be considered in select patients with confirmed GERD, particularly those with incomplete response to medical therapy or who prefer to avoid long-term medication, after objective confirmation of reflux.
• Routine use of adjunctive therapies such as alginates or baclofen is not recommended as first-line treatment but may be considered in specific symptomatic scenarios.
• Extraesophageal symptoms (such as chronic cough or laryngeal symptoms) should not be attributed to GERD without objective evidence of reflux, since empiric PPI response alone is unreliable for this purpose.

What is new in this edition

• Greater emphasis on objective confirmation of reflux (via pH or impedance monitoring) before proceeding to anti-reflux surgery or long-term escalation of therapy.
• Clarified approach to PPI non-responders, focusing on structured diagnostic evaluation rather than empiric dose escalation.
• Reinforced caution about attributing extraesophageal symptoms to reflux without objective testing.

Practice points for students

• Alarm features (dysphagia, weight loss, GI bleeding, anemia) should prompt endoscopy rather than empiric PPI trial.
• A positive response to empiric PPI therapy supports but does not confirm a GERD diagnosis.
• Persistent symptoms despite adequate PPI therapy warrant evaluation for non-acid causes before assuming treatment failure.
• Long-term PPI therapy is not inherently dangerous but should be regularly reviewed for ongoing indication and lowest effective dose.
• Objective reflux testing is key before considering surgical intervention, especially in patients without clear endoscopic evidence of reflux disease.

Condition

Other guidelines on this topic

• Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)NICE2019Summary

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by ACG. It is not medical advice: always read the original guideline before applying it to patients.